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1  |  INTRODUC TION
Dexamethasone, a synthetic corticosteroid, is a commonly used 
veterinary medicine. Injectable preparations require formulation, 
often as esters, to take account of the very limited solubility of 
glucocorticoids in water and to provide a range of formulations 
that extend duration of action (Bishop, 2000). For example, 
dexamethasone sodium phosphate is resorbed rapidly from the 
injection site, thus ensuring a rapid onset of activity, whereas 
dexamethasone phenylpropionate is absorbed more slowly from 
the injection site, thus ensuring a more prolonged duration of 
activity (Australian Pesticides & Veterinary Medicines Authority, 
2002).
There are limited data on the pharmacokinetics of dexametha-
sone in dogs. 1 mg/kg of dexamethasone in alcohol or as isonicoti-
nate was given intravenously or intramuscularly, respectively, to five 
mixed breed dogs (Toutain et al., 1983). Dexamethasone in plasma 
was measured for 10 h after administration, and the limit of quan-
tification (LOQ) was 2 ng/ml. 1 mg of an undefined formulation of 
dexamethasone was injected intramuscularly into 25 greyhounds, 
and urine samples collected for up to 96 h (Hill et al., 1997) with 
dexamethasone being detected for 24 h.
For medication control of drugs for animals used in sport, urine 
is the sample matrix of choice (Morris, 2014). To inform risk assess-
ment for medication control, information on contemporaneous 
plasma (as plasma levels drive effects) and urine levels, after clinical 
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Dexamethasone, formulated as sodium phosphate and as phenylpropionate combined 
with sodium phosphate, was administered subcutaneously to six greyhounds. Plasma 
and urine were collected for up to 240 h and analysed with a limit of quantification 
(LOQ) of at least 100 pg/ml for dexamethasone. Dexamethasone, formulated as so-
dium phosphate, terminal half- life was 10.4 h in plasma and approximately 16 h in 
urine, and at 96 h, plasma hydrocortisone concentrations returned to background 
with dexamethasone levels around the LOQ. Dexamethasone, formulated as phenyl-
propionate combined with sodium phosphate, terminal half- life, was 25.6 h in plasma 
and approximately 26 h in urine, and at 96 h, plasma hydrocortisone concentrations 
returned to background with dexamethasone levels in three of the six greyhounds 
around the LOQ. Critical assessment of the pharmacokinetic and pharmacodynamic 
data indicated how it might be utilized for medication control in racing greyhounds.
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doses of the formulations used by clinicians, that define the terminal 
elimination phases, and with limits of quantification that are appro-
priate for medication control rather than therapeutics, is required.
The primary objective of this study was to describe extended 
plasma and urine concentrations and the pharmacokinetics of dexa-
methasone in greyhound dogs following administration of two 
commonly available commercial injectable preparations of dexa-
methasone, using a highly sensitive analytical assay. A secondary 
objective was to describe the pharmacodynamic effects, specifically 
the suppression of endogenous hydrocortisone. This data could then 
inform discussions of medication control in racing greyhounds.
2  |  MATERIAL S AND METHODS
Dexamethasone was administered as a single dose in two sepa-
rate formulations. 2 mg/ml of dexamethasone sodium phosphate, 
equivalent to 1.52 mg/ml dexamethasone, (Dexadreson® Injection, 
MSD Animal Health Australia, Macquarie Park, NSW [DXD]) was 
given subcutaneously at a dose of 1.52 mg/dog. 1 mg/ml of dex-
amethasone sodium phosphate and 2 mg/ml as dexamethasone 
phenylpropionate, equivalent to 2.26 mg/ml dexamethasone, 
(Dexafort® Injection, MSD Animal Health Australia, Macquarie 
Park, NSW[DXF]) was given subcutaneously at a dose of 1.13 mg/
dog. The two formulations were given at separate times; DXD ad-
ministration was separated by 36 days from the day of DXF admin-
istration. Three neutered female and three entire male greyhounds 
were studied with a mean bodyweight of 32 kg (range 27.8– 37.4 kg) 
and mean age of 3.8 years (range 3– 5 years). Blood and urine were 
collected before drug administration. Blood samples were collected 
after 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 96 h for both formula-
tions. Urine samples were collected after 2, 4, 6, 8, 10, 12, 24, 48, 
72, 96, 120 and 144 h for both formulations, and also at 168, 192, 
216 and 240 h for the DXF formulation. The blood samples were 
heparinized and plasma collected by centrifugation at 4000 rpm (for 
10 min). All samples were stored at −20°C. The frozen samples were 
transported on dry ice to the analytical laboratory.
Dogs were fed a commercial dry dog food (Dogpro PLUS Working 
Dog, Hypro Petcare P/L) with an additional portion of fresh meat, 
with the daily feed ration as two meals and had access to water at all 
times. 100– 200 g of meat was given on the treatment day prior to 
drug administration. The study was conducted in accordance with the 
principles of the VICH GCP guidelines (International Co- operation 
on Harmonisation of Technical Requirements for Registration of 
Veterinary Medicinal Products, Good Clinical Practice, June 2000, 
effective July 2001). Ethics approval (TRIM 15/699(156)) was col-
lected from the Secretary's Animal Care and Ethics Committee of 
the NSW Department of Primary Industry.
Concentrations of dexamethasone and hydrocortisone were mea-
sured in the pre- and post- administration urine and plasma. Urine sam-
ples (1 ml) were diluted with ammonium acetate buffer (0.5 M, pH 5.5, 
6 ml), pH adjusted to 5.5 – 6, and then, enzyme hydrolysed with beta 
glucuronidase. Samples were then extracted on mixed- mode C8- SCX 
columns (Bond Elut- Certify, 130 mg, 3 ml, Agilent, CA, USA) previously 
conditioned with methanol (2 ml) and water (2 ml). After urine loading, 
the column was washed with water (4 ml) then acetic acid (1 M, 2 ml) for 
pH adjustment and dried with nitrogen at 200 ml/sec for 10 min. The 
acid/neutral fraction was eluted with dichloromethane/ethyl acetate 
(4:1, 2 ml) and then washed with sodium hydroxide/sodium chloride 
(1 M/0.15 M, 0.5 ml). The organic layer was removed and evaporated 
under nitrogen at 50°C and reconstituted in formic acid/ammonium 
formate (0.1%) and methanol (50:50) and submitted for LCMS analysis.
Plasma samples (500 µl) were diluted with methanol (150 µl) 
followed by 2% formic acid (3.5 ml) before being transferred to 
solid- phase extraction cartridges (Bond Elut Plexa PCX, 30 mg, 
3 ml, Agilent, CA, USA) previously conditioned with methanol 
(2 ml) followed by formic acid (2%, 2 ml). Cartridges were then 
washed with formic acid (2%, 2 ml) and dried with nitrogen at 
200 ml/sec for 10 min. The acid/neutral fraction was eluted with 
ethyl acetate/methanol (9:1, 2 ml), evaporated under nitrogen 
at 50°C and then reconstituted in formic acid/ammonium for-
mate (0.1%/0.1%) and methanol (50:50) and submitted for LCMS 
analysis.
Urine and plasma extracts were analysed by liquid 
chromatography- mass spectrometry using a Shimadzu 8060 triple 
quadruple mass spectrometer (Shimadzu Corp., Kyoto, Japan) cou-
pled to a Nexera LC- 30AD (Shimadzu Corp., Kyoto, Japan) liquid 
chromatography. The mass spectrometer was operated in multiple 
reaction monitoring (MRM) mode. Electrospray ionization was car-
ried out with heater block, interface and DL temperatures of 300°C, 
300°C and 275°C, respectively. The nebulizer, heating and drying 
gas flow rates were 3, 10 and 5 L/min, respectively.
For urine, dexamethasone was monitored in positive ion mode 
using the de- fluorinated in- source fragment of 373.1 as the pre-
cursor ion and daughter ions m/z 147.1 (for quantification) and 
m/z 171.1 (for identification). The internal standard, dexametha-
sone- d4, was monitored using the transition m/z 377.1 >m/z 149.1. 
Hydrocortisone was monitored in positive ion mode using the 
precursor ion m/z 363.1 and daughter ions m/z 121.1 (for quanti-
fication) and m/z 309.1 (for identification). The internal standard, 
hydrocortisone- d4, was monitored using the transition m/z 364.1 
>m/z 121.1.
For plasma, dexamethasone was monitored in negative ion mode 
using the formate adduct of 437.2 as the precursor ion and daughter 
ion of m/z 361.3. The internal standard, dexamethasone- d4, was mon-
itored using the transition m/z 441.2 >m/z 363.2. Hydrocortisone was 
monitored using the same transitions as the urine method.
Chromatographic separation was achieved using a Poroshell 
120 EC- C18 column (3 mm × 50 mm, 2.7 μm particle size) (Agilent 
Technologies, CA, USA). The mobile phase consisted of formic acid 
(0.1%) and ammonium formate (0.1%) (A) and methanol (B). The ini-
tial composition was 50% B, which was held for 0.3 min and then 
ramped to reach 98% B at 2.5 min. This was held for 1.5 min before 
being returned to 50% B and equilibrated for 1.5 min.
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Calibration ranges, correlation coefficients, limits of quantifica-
tion (LOQ), and detection (LOD) and inter- batch variability of preci-
sion and accuracy for all methods are listed in Table 1.
The PK profiles were analysed with a non- compartmental anal-
ysis using model 200– 202 of Phoenix® WinNonlin® version 8.3 
(Certara USA, Inc., Princeton, NJ) with logarithmic trapezoidal rule. 
Furthermore, the slopes and resulting half- lives for decay phases 
were determined from a linear regression fit to natural log concen-
tration data as the two dexamethasone formulations showed com-
plex decay phases in the plasma data.
Statistical analyses were performed using commercially 
available software (GraphPad Prism version 8.0.0 for Windows, 
GraphPad Software, San Diego, California USA) to assess sig-
nificant differences in hydrocortisone concentrations between 
base line (t = 0) and each time point following dexamethasone 
administration. Data were analysed using mixed- effects analysis 
of variance, with the dog as the random effect and with time as 
the fixed effect. Post hoc comparisons were performed with a 
Dunnett's multiple- comparison test to preserve a nominal signif-
icance of 0.05.
3  |  RESULTS
The elimination profile in six greyhounds after dexamethasone 
sodium phosphate administration (DXD— Dexadreson® formula-
tion) in plasma and urine are shown in Figure 1 (first 24 h shown in 
Appendix S1) and the pharmacokinetic parameters are in Table 2. 
TA B L E  1  Calibration ranges, limits of quantification (LOQ), limits of detection (LOD), correlation coefficients (R2), inter- batch variability of 
precision and accuracy for the analysis of dexamethasone and hydrocortisone in plasma and urine
Plasma Range LOQ LOD R2 Precision (% CV) Accuracy
Dexamethasone 0– 10 ng/ml 0.01 ng/ml 0.01 ng/ml >.99 8.1% 5.4%
Hydrocortisone 0– 10 ng/ml 0.5 ng/ml 0.1 ng/ml >.99 0.9% 6.0%
Urine Range LOQ LOD R2 Precision (% CV) Accuracy
Dexamethasone 0– 500 ng/ml 0.1 ng/ml 0.1 ng/ml >.99 12.8% 8.2%
Hydrocortisone 0– 200 ng/ml 0.5 ng/ml 0.25 ng/ml >.99 11.7% 12.7%
F I G U R E  1  Mean dexamethasone 
(filled symbols) and hydrocortisone (open 
symbols) concentration in plasma (circle 
symbols) and urine (square symbols) after 
administration of dexamethasone sodium 
phosphate (DXD) to six greyhounds






(mL/min/Kg) HL1 (hrs) HL2 (hrs) HL3 (hrs)
1 34.7 37.2 8.75 0.427 2.23 10.7
2 29.8 39.7 9.81 0.61 2.55 9.28
3 36.8 46.7 8.14 0.379 2.23 11.0
4 33.5 32.9 9.44 0.43 2.36 5.96
5 29.4 29.2 11.5 0.489 2.68 13.8
6 27.8 43.3 7.98 0.453 2.79 14.2
Mean 32.0 38.2 9.27 0.455a  2.45a  9.95a 
Median 31.7 38.4 9.09 0.442 2.46 10.8
Note: Cmax (peak plasma concentration), CL/F (mean apparent clearance adjusted for bioavailability), HL (half- life for each successive decay phase).
aHarmonic mean. 
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Dexamethasone concentrations in plasma reach their peak by 15 min 
post- administration before declining rapidly, with a harmonic mean 
half- life of 0.46 h. At approximately 2 h, there appears to be a sec-
ond slower decay phase which flattens between 6 and 8 h, with a 
geometric mean half- life of 2.45 h and then further decays into an 
even slower third phase, with a harmonic mean half- life of 9.95 h. 
The mean apparent clearance adjusted for subcutaneous bioavail-
ability was 9.27 ml/min/Kg. Dexamethasone concentrations in urine 
increase rapidly over the first 2– 4 h before declining and then flatten 
between 6 and 12 h. This is then followed by a slower second decay 
phase with an approximate half- life of 16 h, a similar order to the 
half- life for the third- decay phase observed in plasma. Figure 1 also 
shows how hydrocortisone concentrations decrease rapidly after 
the administration of DXD and then stay below the LOD until 24 h. 
After this time, hydrocortisone concentrations start to rise and all 6 
dogs appear to return to background levels by 96 h; however, statis-
tically significant differences from baseline using the Dunnett's post 
hoc test are only observed between 2 and 24 h.
The elimination profile in six greyhounds after dexamethasone 
sodium phosphate and dexamethasone phenylpropionate, adminis-
tration (DXF— Dexafort® formulation) in plasma and urine are shown 
in Figure 2 (first 24 h shown in Appendix S1) and the pharmacoki-
netic parameters are in Table 3. Dexamethasone plasma concen-
trations increase rapidly over the first 2 h before declining rapidly 
with a harmonic mean half- life of 1.95 h. At approximately 8 h, there 
appears to be a second phase of absorption with dexamethasone 
concentrations increasing until 12 h followed by a slower decline, 
with a harmonic mean half- life of 25.3 h. The mean apparent clear-
ance adjusted for subcutaneous bioavailability was 16.0 ml/min/
Kg. Dexamethasone urine concentrations increase rapidly over the 
first 2 h before declining, and at approximately 8 h, there appears 
to be a second phase of absorption although less pronounced than 
in plasma. At 12 h, urine concentrations decline with a half- life of 
approximately 25 h, which is very similar to the second phase plasma 
half- life. At 100 h post- administration, the urine pharmacokinetics 
enters a very long phase with a half- life of approximately 200 h. 
Figure 2 also shows how hydrocortisone concentrations decrease 
rapidly after the administration of DXF and then stay below the LOD 
until 8 h. After this time, hydrocortisone concentrations start to rise 
and 3 out of the 6 dogs appear to return to background by 96 h; 
however, statistically significant differences from baseline using the 
Dunnett's post hoc test are only observed between 2 and 24 h.
4  |  DISCUSSION
The data produced in this study were compatible with the much more 
limited existing data that have informed clinical usage for many years 
(Hill et al., 1997; Toutain et al., 1983): For example, Toutain et al., 1984 
determined a clearance of 6.4 ml/min/kg for IV administration of dexa-
methasone to dogs. This study herein usefully extends the duration of 
plasma data, adds extended urine data, as well as an indication of one 
component of the pharmacodynamic effect by measuring the reduction 
in endogenous hydrocortisone. As such, it addressed the primary and 
secondary objectives set out for this study and makes this information 
available for wider scientific and clinical use. Moreover, the data from 
this study can be combined with existing and future data and analysed 
using a population approach such as Non- Linear Mixed Effects (NLME) 
methodology (Schoemaker & Cohen, 1996). NLME is appropriate for 
analysing unbalanced data sets collected with analytical techniques of 
different sensitivity, but having generated similar data above the LOQ. 
Such an aggregation of data will solve the question of low statistical 
power of individual data sets and will facilitate harmonization between 
regulatory jurisdictions.
The data from this study also provide scientific information for 
the first stage, risk assessment (Toutain, 2010), of medication con-
trol. There are two established methodologies to derive medica-
tion control parameters from such administration studies (Toutain, 
2013). The first methodology used in most horse and greyhound 
regulatory jurisdictions is to use the data to estimate the effective 
plasma concentration (EPC), irrelevant plasma concentration (IPC), 
irrelevant urine concentration (IUC) and so derive a screening limit 
(SL) and detection time (DT) (Toutain & Lassourd, 2002). The second 
methodology used in US horseracing is similar to that used for deter-
mining drug residues in meat for human safety such that, with a risk 
of ⩽5%, that at least 95% of the animal population is under the spec-
ified drug level as for example used for dexamethasone (European 
Agency for the Evaluation of Medicinal Products & Committee for 
Veterinary Medicinal Products, 1997). It is important to be clear on 
the methodology used, for example, the latter approach can tend be 
F I G U R E  2  Mean dexamethasone 
(filled symbols) and hydrocortisone (open 
symbols) concentration in plasma (circle 
symbols) and urine (square symbols) 
after administration of dexamethasone 
sodium phosphate and dexamethasone 
phenylpropionate (DXF) to six greyhounds
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more permissive in terms of drug levels, which will be an important 
factor in the second stage of medication control; risk management 
by regulators informed by scientific advice (Toutain, 2013).
A considerable body of published medication control parame-
ters using the former methodology (EPC, IPC, IUC, SL, DT) is being 
utilized by regulators in horse racing and now in greyhound racing. 
However, using this approach can be questioned in some situations. 
With drugs that act both locally and systemically, such as glucocor-
ticoids, there is no single concentration value which covers every 
site of action and the use of an IPC/IUC may be challenged (Toutain, 
2010), although it has already been used in respect of dexametha-
sone isonicotinate in racehorses (Ekstrand et al., 2015).
Most administration studies for medication control focus on drug 
pharmacokinetics and do not include pharmacodynamic measure-
ments. Glucocorticoids have both rapid and slower pharmacodynamic 
effects and the Toutain and Lassourd (2002) methodology also may not 
be appropriate if there is significant hysteresis. Rapid, non- genomic glu-
cocorticoid actions are mediated through physiochemical interactions 
with cytosolic glucocorticoid receptor (GR) or membrane- bound GR. 
Non- genomic effects of glucocorticoids do not require protein synthe-
sis and occur within seconds to minutes of GR activation. For example, 
when released from the inactive GR protein complex, the non- receptor 
tyrosine kinase protein c- Src activates signalling cascades that inhibit 
phospholipase A2 activity, phosphorylate annexin 1 and impair the 
release of arachidonic acid. Slower genomic effects of glucocorticoids 
involve binding to GR followed by translocation to the nucleus. Once 
inside the nucleus, GR binds directly to glucocorticoid- responsive el-
ements (GREs) and stimulates target gene expression followed by 
protein synthesis, and therefore, there can be a delay in some effects. 
However, most of the anti- inflammatory effects of glucocorticoids ap-
pear to result from an important negative regulatory mechanism called 
transrepression, in which GR directly interferes with the transcriptional 
activation of key inflammatory proteins.
Therefore, if pharmacodynamic parameters are considered 
rather than pharmacokinetic alone, this can significantly affect a 
determination of medication control information (Knych et al., 2020). 
However, with corticoids having a complex array of PD effects, there 
is a question with regard to which effects should be considered. For 
instance, in the herein study it is clear that inhibition of hydrocortisone 
in plasma occurs rapidly (statistically significant at 2 h). This has also 
been shown in horses where significant inhibition of hydrocortisone 
was observed in a few hours (Ekstrand et al., 2015; Knych et al., 2020). 
Initial suppression of hydrocortisone is rapid because dexamethasone 
causes incremental inhibition for as long as dexamethasone plasma 
concentrations are greater than the IC50. However, the maximum ob-
served suppression of hydrocortisone occurs much later than the time 
of occurrence of maximum dexamethasone plasma concentrations 
(time =0) because after hydrocortisone suppression reaches a maxi-
mum the return to baseline is then a function of both the rate of hy-
drocortisone production and dexamethasone elimination. Therefore, 
the response lasts beyond the presence of effective dexamethasone 
concentrations because of the time needed for the system to equili-
brate (Sharma & Jusko, 1998).
While statistically significant differences from baseline were only 
observed between 2 and 24 h, six dogs may not be statistically pow-
erful enough, given the number of comparisons prepared in the post 
hoc Dunnett's test, to reject the null hypothesis for later time points. 
Moreover, caution must be applied as ‘not statistically different’ is in-
sufficient to conclude equivalence to baseline. The limited statistical 
power of this trial (6 dogs) prevents the conclusion that the hydro-
cortisone plasma concentrations at ≥48 h are significantly lower than 
baseline values. On the other hand, a conclusion that the difference is 
‘statistically significant’ (eg 24 h) means there is strong evidence that 
the difference is not zero, but it will not be known whether the dif-
ference is large enough to be clinically or scientifically indistinguish-
able. With a limitation of 6 dogs, a simple a priori contrast approach 
could be applied to hydrocortisone levels using a t test comparison at 
a specified day (e.g. day 3 or 4) relative to pre- dose control. However, 
t tests between control and day 3 or 4 were not statistically signif-
icant but were significant for day 2. More complex linear contrast 
approaches where data are weighted by sets of contrasts could be 
applied and offer more power against Type II errors, especially if sev-
eral control values of hydrocortisone were collected prior to adminis-
tration. Therefore, caution must be applied to the herein results when 
interpreting the duration of hydrocortisone suppression.
The reported IC50 values for inhibition of hydrocortisone pro-
duction were very different between the Ekstrand et al., 2015 study 
(0.06 ng/ml) and the Knych et al., 2020 study (0.007 ng/ml). An es-
timate of the IC50 for the herein Greyhound study is approximately 
0.1 ng/ml using an indirect response model for the average data and 
occurs at 48 h post- administration.
Furthermore, the Knych et al., 2020 investigation examined the 
effect of dexamethasone on inflammatory stimulated whole blood 
and showed that key bio- markers of inflammation such as prosta-
glandins and metabolites of arachidonic acid where significantly 
reduced within 2– 4 h of administration. This is consistent with the 
known rapid transrepression anti- inflammatory effects of glucocor-
ticoids discussed above.
TA B L E  3  Non- compartmental parameters for dexamethasone 
after administration of dexamethasone sodium phosphate and 












1 34.7 4.27 17.4 2.35 27.5
2 29.8 5.89 15.9 2 21.3
3 36.8 4.09 12.6 2.39 33.1
4 33.5 4.34 21.7 1.74 20.3
5 29.4 4.36 16.5 1.76 26.3
6 27.8 4.60 12.0 1.69 27.5
Mean 32 4.59 16.0 1.95a  25.3a 
Median 31.65 4.35 16.2 1.88 26.9
Note: Cmax (peak plasma concentration), CL/F (mean apparent 
clearance adjusted for bioavailability), HL (half- life for each successive 
decay phase).
aHarmonic mean. 
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Given that the major anti- inflammatory effects and inhibition of 
hydrocortisone production by dexamethasone are rapid processes 
and that clinical indications in racing greyhounds relate to the ad-
ministration of either DXD or DXF to greyhounds for their systemic 
anti- inflammatory effects, for example, its use for medial tibial peri-
ostitis, there is a strong case that in these circumstances the Toutain 
method has validity for medication control in racing greyhounds as it 
is in racing horses (Ekstrand et al., 2015).
In conclusion, this study makes available for dexamethasone, 
in widely available commercial formulations, extended plasma 
data, adds extended urine data, as well as providing an indication 
of one component of the pharmacodynamic effect by measuring 
the reduction in endogenous hydrocortisone. Greyhound racing 
regulators also now have the option of using this risk assessment 
information for risk management to decide an analytical cut- off 
value for screening of medications (Toutain, 2010). Further infor-
mation on risk management using the methodology described by 
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